Evidence map›Paper›PMID 37547754›Full record

ArticleOncology research2023

Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.

Wenhao Xu, Haoming Li, Yasir Hameed, Mostafa A Abdel-Maksoud, Saeedah Musaed Almutairi, Ayman Mubarak, Mohammed Aufy, Wael Alturaiki, Abdulaziz J Alshalani, Ayman M Mahmoud and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenhao XuDepartment of Urology, Urological Surgery Research Institute, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Haoming LiDepartment of Urology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Yasir HameedDepartment of Applied Biological Sciences, Tokyo University of Science, Tokyo, Japan.
Mostafa A Abdel-MaksoudDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Saeedah Musaed AlmutairiDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Ayman MubarakDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Mohammed AufyDepartment of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Wael AlturaikiDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Abdulaziz J AlshalaniDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Ayman M MahmoudDepartment of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.
Chen LiDepartment of Biology, Chemistry, Pharmacy, Free University of Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern in specific malignancies. We found two independent patterns of m6A alteration in ACC patients. The TME cell infiltration features were significantly in accordance with phenotypes of tumor immune-inflamed and immune desert in both patterns. The m6Ascore also served as an independent predictive factor in ACC patients. The somatic copy number variation (CNV) and patients prognosis can be predicted by m6A alteration patterns. Moreover, the ACC patients with high m6A scores had better overall survival (OS) and higher efficiency in immune checkpoint blockade therapy. Our work demonstrated the significance of m6A alteration to the ACC patients immunotherapy. The individual m6A alteration patterns analysis might contribute to ACC patients prognosis prediction and immunotherapy choice.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAdenosineDNA Copy Number VariationsHumansMethylationTumor MicroenvironmentAdenosineN-methyladenosineAdrenocortical carcinomaImmunotherapym6APrognosisTumor microenvironment

Identifiers

PMID37547754
PMCPMC10398396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.